Home

Characterization of immune responses correlating with protection and the development of an efficacious treatment against Ebola virus infections

Show simple item record

dc.contributor.supervisor Kobinger, Gary (Medical Microbiology) en_US
dc.contributor.author Wong, Gary Chung Kei
dc.date.accessioned 2014-09-05T14:51:02Z
dc.date.available 2014-09-05T14:51:02Z
dc.date.issued 2014-09-05
dc.identifier.uri http://hdl.handle.net/1993/23976
dc.description.abstract Ebola virus (EBOV) is a zoonotic pathogen which causes a fulminant hemorrhagic fever and results in up to 90% fatality. Despite efforts over the past 38 years, a licensed prophylactic or post-exposure option remains unavailable. Several experimental vaccines have already demonstrated protection from lethal EBOV disease in nonhuman primates (NHPs). However, attempts to translate this research from bench to bedside have been hampered, since the immune responses that correlate with protection against EBOV are not well-defined. Without this information, it is not possible to reliably predict the efficacy of vaccines or treatments in humans without lethal challenge. The goal of this thesis is to determine the immune parameters that are predictive of protection against EBOV. Due to the rapid speed of EBOV pathogenesis, it was originally hypothesized that a rapid and robust CD8+ T-cell response must be crucial for survival. Using a previously-characterized adenovirus-vectored Ebola vaccine (Ad5-optGP), transgenic/knockout C57BL/6J mice with ablation for selected immune responses were vaccinated and challenged 28 days later. Surprisingly, while CD8+ T-cell knockout mice survived infection, B-cell knockout mice did not, indicating that the antibody response played a critical role in protection. Humoral and cell-mediated responses were compared between survivor and moribund guinea pigs and NHPs from previous vaccination and post-exposure therapy experiments, either with Ad5-optGP or a vesicular stomatitis virus (VSV)-vectored vaccine (VSVΔG/EBOVGP). Circulating EBOV glycoprotein (GP)-specific IgG antibody levels were the best correlation for protection independent of vaccine platform or timing of exposure (p<0.0001), strongly supporting the role of antibody responses in the control of EBOV infection. To demonstrate that antibodies are also responsible for protection, three previously-characterized monoclonal antibodies recognizing different GP epitopes were combined into a cocktail (ZMAb). Initiation of ZMAb treatment 1 and 2 days post infection (dpi) with EBOV protected 100% and 50% of NHPs, respectively. These results provide a reliable measure for predicting protection from EBOV in three commonly used animal models, and present a strong case for the use of antibodies as an effective post-exposure treatment. This knowledge will ultimately help in the development and validation of a clinical product against EBOV infection. en_US
dc.subject Ebola en_US
dc.subject vaccines en_US
dc.subject B-cells en_US
dc.subject T-cells en_US
dc.subject antibody en_US
dc.subject treatment en_US
dc.subject ZMAb en_US
dc.subject correlates for protection en_US
dc.subject rodents en_US
dc.subject nonhuman primates en_US
dc.title Characterization of immune responses correlating with protection and the development of an efficacious treatment against Ebola virus infections en_US
dc.degree.discipline Medical Microbiology en_US
dc.contributor.examiningcommittee Coombs, Kevin (Medical Microbiology) Kung, Sam (Immunology) Bretscher, Peter (University of Saskatchewan) en_US
dc.degree.level Doctor of Philosophy (Ph.D.) en_US
dc.description.note October 2014 en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

View Statistics